NCT03269578 Sample Collection and Tracking for the Developmental Therapeutics Clinic
| NCT ID | NCT03269578 |
| Status | Recruiting |
| Phase | — |
| Sponsor | National Cancer Institute (NCI) |
| Condition | Neoplasms |
| Study Type | OBSERVATIONAL |
| Enrollment | 3,000 participants |
| Start Date | 2017-08-28 |
| Primary Completion | 2027-05-23 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 3,000 participants in total. It began in 2017-08-28 with a primary completion date of 2027-05-23.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Background: People who join a study in the Developmental Therapeutics Clinic (DTC) have tests. These include blood draws and biopsies. Researchers collect data from these samples. Some people take part in more than one study at the DTC. At this time, data are connected only with one single study. Researchers want to access people s medical records. This will allow them to link the research data from all their studies they have or will take part in. Researchers also want to collect medical data about their diagnosis and treatment history. This will allow them to see how their cancer reacted to different drugs over time. Objective: To enter people into a master protocol to connect research sample and treatment data across DTC studies. Eligibility: People ages 18 and older who are being evaluated or treated for cancer in the DTC Design: Participants will allow researchers to look at all the data from their research samples. This includes those from their current, past, and any future NIH studies. Participants will allow researchers to access some of their medical data. This includes age, diagnosis, treatment history, and response to treatment. Participants will provide no new samples. ...
Eligibility Criteria
* INCLUSION CRITERIA: * Patients who are being evaluated and/or treated for cancer or benign tuumors in the Developmental Therapeutics Clinic at the NIH Clinical Center * Ability to understand and willingness to sign a written informed consent document indicating their willingness to have data from their tissue or biologic fluid research specimens and limited medial information used for research as outlined in this protocol and to allow protocol staff access to the CRIS database and their Medical Records Number (MRN). * Age greater than or equal to 18 years ECLUSION CRITERIA: None
Contact & Investigator
Alice P Chen, M.D.
PRINCIPAL INVESTIGATOR
National Cancer Institute (NCI)
Frequently Asked Questions
Who can join the NCT03269578 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 120 Years, studying Neoplasms. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03269578 currently recruiting?
Yes, NCT03269578 is actively recruiting participants. Contact the research team at zlottjh@mail.nih.gov for enrollment information.
Where is the NCT03269578 trial being conducted?
This trial is being conducted at Bethesda, United States.
Who is sponsoring the NCT03269578 clinical trial?
NCT03269578 is sponsored by National Cancer Institute (NCI). The principal investigator is Alice P Chen, M.D. at National Cancer Institute (NCI). The trial plans to enroll 3,000 participants.